|
業務類別
|
Biotechnology |
|
業務概覽
|
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis. |
| 公司地址
| 40 Erie Street, Suite 130, Cambridge, MA, USA, 02139 |
| 電話號碼
| +1 857 285-6200 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.intelliatx.com |
| 員工數量
| 377 |
| Ms. Birgit Schultes |
Executive Vice President and Chief Scientific Officer |
美元 475.00K |
30/04/2026 |
| Mr. Michael P. Dube |
Vice President and Chief Accounting Officer |
-- |
30/04/2026 |
| Ms. Eliana Clark |
Executive Vice President and Chief Technology Officer |
-- |
30/04/2026 |
| Dr. David Lebwohl, M.D. |
Executive Vice President and Chief Medical Officer |
美元 536.00K |
30/04/2026 |
| Mr. James Basta, J.D. |
Executive Vice President, General Counsel and Corporate Secretary |
美元 494.00K |
30/04/2026 |
| Dr. John M. Leonard, M.D. |
Director, President and Chief Executive Officer |
美元 708.00K |
30/04/2026 |
| Mr. Edward J. Dulac, III |
Treasurer, Executive Vice President and Chief Financial Officer |
美元 526.00K |
30/04/2026 |
|
|
| Dr. Fred E. Cohen, D.Phil.,F.A.C.P.,M.D. |
Independent Director |
30/04/2026 |
| Mr. William J. Chase |
Independent Director |
30/04/2026 |
| Ms. Muna Bhanji, Ph. |
Independent Director |
30/04/2026 |
| Dr. Georgia Keresty, M.P.H.,PhD |
Independent Director |
30/04/2026 |
| Dr. Jesse Goodman, M.D.,M.P.H. |
Independent Director |
30/04/2026 |
| Dr. Frank Verwiel, M.B.A.,M.D. |
Chairman of the Board |
30/04/2026 |
| Dr. John M. Leonard, M.D. |
Director, President and Chief Executive Officer |
30/04/2026 |
| Mr. Brian Goff |
Independent Director |
30/04/2026 |
|
|
|
|
